drugset
drugset / Trial / NCT06052813

A Study of BN104 in the Treatment of Acute Leukemia

NCT06052813 ↗

Phase 1/2 Active not recruiting 66 enrolled Servier
Non-randomizedSequentialOpen-labelTreatment

Summary

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.

Timeline

Start
2023-10-19
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BN104 Small molecule 200 mg Oral
Subject BN104 Small molecule 300 mg Oral
Subject BN104 Small molecule 400 mg Oral
Subject BN104 Small molecule 600 mg Oral
Subject BN104 Small molecule 800 mg Oral

Indications

acute myeloid leukemia with NPM1 somatic mutations adult acute lymphoblastic leukemia